Bipartisan Push for Medicare Coverage of Alzheimer's Blood Tests Gains Momentum

Key points

• The ASAP Act, co-sponsored by Reps. Vern Buchanan and Paul Tonko, seeks to authorize Medicare coverage for blood-based biomarker tests for early Alzheimer's detection.
• Currently, Medicare only covers preventive services explicitly authorized by Congress or recommended by the U.S. Preventive Services Task Force, delaying access to new FDA-cleared tests.
• Over 7 million Americans live with Alzheimer's, a number expected to double in coming decades, with projected national costs exceeding $1 trillion by 2050.
• The bill has 224 House co-sponsors, indicating broad bipartisan support for preventive healthcare and fiscal responsibility.
• Critics note that while early detection is vital, current treatments like donanemab and lecanemab are costly, have significant side effects, and exclude approximately 90% of patients in some markets.

Background

Recent archive coverage highlights a broader trend of voter distrust in both major parties, yet the ASAP Act represents a rare area of bipartisan consensus. Unlike previous gridlock on other issues, this healthcare measure aligns with shared values of prevention and cost-effectiveness, potentially bypassing the political polarization seen in other legislative areas.

How outlets are covering it

The Washington Post emphasizes the legislative urgency and fiscal responsibility of the ASAP Act, framing it as a necessary update to Medicare policies. The NIH highlights the scientific validity of combining blood biomarkers (p-tau217) with APOE-ε4 genetic status to predict dementia risk, noting a 3-4 year window between elevated biomarkers and symptom onset. InForum underscores the human impact, urging local representatives to support the bill to prevent late-stage diagnoses. The Australian Financial Review provides a critical counter-perspective, noting that while new drugs like donanemab and lecanemab slow decline, they are prohibitively expensive, cause severe side effects like brain swelling, and exclude many patients, suggesting that detection alone does not guarantee accessible treatment.

Why it matters

The ASAP Act addresses a critical gap between medical innovation and insurance coverage. By enabling early detection through affordable blood tests, the legislation could reduce the massive economic and social burden of late-stage dementia care. It also highlights the growing importance of preventive healthcare in an aging population, where early intervention can significantly alter disease trajectories and improve quality of life for millions of families.

What to watch

The immediate focus is on passing the ASAP Act before the end of the year. Lawmakers will need to navigate the legislative process to ensure the bill becomes law, potentially requiring further debate on the scope of Medicare coverage for new diagnostic technologies. Additionally, ongoing research into more effective and safer treatments, such as trontinemab and mRNA vaccines, will be crucial to making early detection actionable for a broader population.